The stock of Sigilon Therapeutics Inc. (NASDAQ:SGTX) last traded at $1.14, down -1.72% from the previous session.
Data from the available sources indicates that Sigilon Therapeutics Inc. (NASDAQ:SGTX) is covered by 4 analysts. The consensus rating among analysts is ‘Overweight’. SGTX stock price is now 54.91% away from the 50-day moving average and 75.16% away from the 200-day moving average. The market capitalization of the company currently stands at $43.75M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 1 analysts have assigned it a hold rating, and 2 have given it a buy rating.
With the price target reduced from $15 to $4, Jefferies Downgraded its rating from Buy to Hold for Sigilon Therapeutics Inc. (NASDAQ: SGTX). On October 29, 2021, BTIG Research recently initiated its ‘Buy’ rating on the stock quoting a target price of $14, while ‘Jefferies’ rates the stock as ‘Buy’.
A total of 13.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SGTX stock. A new stake in Sigilon Therapeutics Inc. shares was purchased by CERCANO MANAGEMENT LLC during the first quarter worth $1,009,000. CITADEL ADVISORS LLC invested $38,000 in shares of SGTX during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in Sigilon Therapeutics Inc. valued at approximately $13,000. AMALGAMATED FINANCIAL CORP. acquired a new stake in SGTX for approximately $2,000. In total, there are 49 active investors with 52.20% ownership of the company’s stock.
With an opening price of $1.1400 on Wednesday morning, Sigilon Therapeutics Inc. (NASDAQ: SGTX) set off the trading day. During the past 12 months, Sigilon Therapeutics Inc. has had a low of $0.29 and a high of $1.75. As of last week, the company has a debt-to-equity ratio of 0.46, a current ratio of 2.60, and a quick ratio of 2.60. The fifty day moving average price for SGTX is $0.7517 and a two-hundred day moving average price translates $0.6527 for the stock.
The latest earnings results from Sigilon Therapeutics Inc. (NASDAQ: SGTX) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.27, beating analysts’ expectations of -$0.42 by 0.15. This compares to -$0.55 EPS in the same period last year. The company reported revenue of $2.64 million for the quarter, compared to $1.99 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 32.86 percent. For the current quarter, analysts expect SGTX to generate $2.67M in revenue.
Sigilon Therapeutics Inc.(SGTX) Company Profile
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
